468 related articles for article (PubMed ID: 37037791)
1. Omicron BA.1 breakthrough infections in inactivated COVID-19 vaccine recipients induced distinct pattern of antibody and T cell responses to different Omicron sublineages.
Guo L; Zhang Q; Zhong J; Chen L; Jiang W; Huang T; Li Y; Zhang Y; Xu L; Wang X; Xiao Y; Wang Y; Dong X; Dong T; Peng Y; Zhang B; Xie Y; Gao H; Shen Z; Ren L; Cheng T; Wang J
Emerg Microbes Infect; 2023 Dec; 12(1):2202263. PubMed ID: 37037791
[TBL] [Abstract][Full Text] [Related]
2. Progressive loss of conserved spike protein neutralizing antibody sites in Omicron sublineages is balanced by preserved T cell immunity.
Muik A; Lui BG; Quandt J; Diao H; Fu Y; Bacher M; Gordon J; Toker A; Grosser J; Ozhelvaci O; Grikscheit K; Hoehl S; Kohmer N; Lustig Y; Regev-Yochay G; Ciesek S; Beguir K; Poran A; Vogler I; Türeci Ö; Sahin U
Cell Rep; 2023 Aug; 42(8):112888. PubMed ID: 37527039
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 Omicron infection augments the magnitude and durability of systemic and mucosal immunity in triple-dose CoronaVac recipients.
Chen Y; Zhao T; Chen L; Jiang G; Geng Y; Li W; Yin S; Tong X; Tao Y; Ni J; Lu Q; Ning M; Wu C
mBio; 2024 Apr; 15(4):e0240723. PubMed ID: 38456703
[TBL] [Abstract][Full Text] [Related]
4. Neutralizing Antibody Responses against Five SARS-CoV-2 Variants and T Lymphocyte Change after Vaccine Breakthrough Infections from the SARS-CoV-2 Omicron BA.1 Variant in Tianjin, China: A Prospective Study.
Zhang Y; Qu JW; Zheng MN; Ding YX; Chen W; Ye SD; Li XY; Li YK; Liu Y; Zhu D; Jin CR; Wang L; Yang JY; Zhai Y; Wang EQ; Meng X
Biomed Environ Sci; 2023 Jul; 36(7):614-624. PubMed ID: 37533385
[TBL] [Abstract][Full Text] [Related]
5. Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination
Wang H; Xue Q; Zhang H; Yuan G; Wang X; Sheng K; Li C; Cai J; Sun Y; Zhao J; Lu J; Fang S; Yang Y; Zhang Y; Huang Y; Wang J; Xu JH; Jiang MX; Wang X; Shen L; Liu Y; Liu Q; Zhang Q; Wang S; Wang P; Qiu C; Ai J; Zhang W
Emerg Microbes Infect; 2023 Dec; 12(2):2249121. PubMed ID: 37668156
[TBL] [Abstract][Full Text] [Related]
6. Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5.
Diem G; Jäger M; Dichtl S; Bauer A; Lass-Flörl C; Reindl M; Wilflingseder D; Posch W
Microbiol Spectr; 2023 Jun; 11(3):e0516322. PubMed ID: 37098903
[TBL] [Abstract][Full Text] [Related]
7. Durability and cross-reactive immune memory to SARS-CoV-2 in individuals 2 years after recovery from COVID-19: a longitudinal cohort study.
Guo L; Zhang Q; Gu X; Ren L; Huang T; Li Y; Zhang H; Liu Y; Zhong J; Wang X; Chen L; Zhang Y; Li D; Fang M; Xu L; Li H; Wang Z; Li H; Bai T; Liu W; Peng Y; Dong T; Cao B; Wang J
Lancet Microbe; 2024 Jan; 5(1):e24-e33. PubMed ID: 38048805
[TBL] [Abstract][Full Text] [Related]
8. Prototype and BA.5 protein nanoparticle vaccines protect against Omicron BA.5 variant in Syrian hamsters.
Bricker TL; Joshi A; Soudani N; Scheaffer SM; Patel N; Guebre-Xabier M; Smith G; Diamond MS; Boon ACM
J Virol; 2024 Mar; 98(3):e0120623. PubMed ID: 38305154
[TBL] [Abstract][Full Text] [Related]
9. Significant neutralizing escapes of Omicron and its sublineages in SARS-CoV-2-infected individuals vaccinated with inactivated vaccines.
Shen F; Yang CX; Lu Y; Zhang M; Tian RR; Dong XQ; Li AQ; Zheng YT; Pang W
J Med Virol; 2023 Feb; 95(2):e28516. PubMed ID: 36680413
[TBL] [Abstract][Full Text] [Related]
10. Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice.
Muik A; Lui BG; Bacher M; Wallisch AK; Toker A; Couto CIC; Güler A; Mampilli V; Schmitt GJ; Mottl J; Ziegenhals T; Fesser S; Reinholz J; Wernig F; Schraut KG; Hefesha H; Cai H; Yang Q; Walzer KC; Grosser J; Strauss S; Finlayson A; Krüger K; Ozhelvaci O; Grikscheit K; Kohmer N; Ciesek S; Swanson KA; Vogel AB; Türeci Ö; Sahin U
Sci Immunol; 2022 Dec; 7(78):eade9888. PubMed ID: 36378074
[TBL] [Abstract][Full Text] [Related]
11. Three-dose vaccination-induced immune responses protect against SARS-CoV-2 Omicron BA.2: a population-based study in Hong Kong.
Zhou R; Liu N; Li X; Peng Q; Yiu CK; Huang H; Yang D; Du Z; Kwok HY; Au KK; Cai JP; Fan-Ngai Hung I; Kai-Wang To K; Xu X; Yuen KY; Chen Z
Lancet Reg Health West Pac; 2023 Mar; 32():100660. PubMed ID: 36591327
[TBL] [Abstract][Full Text] [Related]
12. Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5.
Bormann M; Brochhagen L; Alt M; Otte M; Thümmler L; van de Sand L; Kraiselburd I; Thomas A; Gosch J; Braß P; Ciesek S; Widera M; Dolff S; Dittmer U; Witzke O; Meyer F; Lindemann M; Schönfeld A; Rohn H; Krawczyk A
Front Immunol; 2023; 14():1150667. PubMed ID: 37520539
[TBL] [Abstract][Full Text] [Related]
13. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
[TBL] [Abstract][Full Text] [Related]
14. Effect of vaccine booster, vaccine type, and hybrid immunity on humoral and cellular immunity against SARS-CoV-2 ancestral strain and Omicron variant sublineages BA.2 and BA.5 among older adults with comorbidities: a cross sectional study.
Fong CH; Zhang X; Chen LL; Poon RW; Chan BP; Zhao Y; Wong CK; Chan KH; Yuen KY; Hung IF; Yuen JKY; To KK
EBioMedicine; 2023 Feb; 88():104446. PubMed ID: 36706582
[TBL] [Abstract][Full Text] [Related]
15. Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5.
Muik A; Lui BG; Bacher M; Wallisch AK; Toker A; Finlayson A; Krüger K; Ozhelvaci O; Grikscheit K; Hoehl S; Ciesek S; Türeci Ö; Sahin U
Sci Immunol; 2022 Nov; 7(77):eade2283. PubMed ID: 36125366
[TBL] [Abstract][Full Text] [Related]
16. Distinct features of SARS-CoV-2 humoral immunity against Omicron breakthrough infection.
Goto T; Chong Y; Tani N; Susai N; Yoshinaga T; Sasaki T; Taniguchi M; Kusakabe T; Shimono N; Akashi K; Ikematsu H
Vaccine; 2023 Nov; 41(47):7019-7025. PubMed ID: 37858449
[TBL] [Abstract][Full Text] [Related]
17. Assessment of antibody responses against SARS-CoV-2 in unvaccinated individuals and vaccinees from Omicron-BA.2 infection in Zhaoqing, Guangdong Province, China.
Zhang H; Jiang Y; Tan H; Zou L; Zheng Z; Huang Y; Lin S; Su L; Yu J; Deng X; He J; Liu C; Shen C; Li B
Virol J; 2022 Nov; 19(1):197. PubMed ID: 36434614
[TBL] [Abstract][Full Text] [Related]
18. Humoral and cellular immunogenicity of homologous and heterologous booster vaccination in Ad26.COV2.S-primed individuals: Comparison by breakthrough infection.
Hyun H; Jang AY; Park H; Heo JY; Seo YB; Nham E; Yoon JG; Seong H; Noh JY; Cheong HJ; Kim WJ; Yoon SY; Seok JH; Kim J; Park MS; Song JY
Front Immunol; 2023; 14():1131229. PubMed ID: 36960070
[TBL] [Abstract][Full Text] [Related]
19. Omicron variants breakthrough infection elicited higher specific memory immunity than third dose booster in healthy vaccinees.
Yu P; Liu Z; Zhu Z; Yang J; Deng M; Chen M; Lai C; Kong W; Xiong S; Wan L; Mai W; Chen L; Lei Y; Khan SA; Ruan J; Kang A; Guo X; Zhou Q; Li W; Chen Z; Liang Y; Li P; Zhang L; Ji T
Virol Sin; 2023 Apr; 38(2):233-243. PubMed ID: 36603767
[TBL] [Abstract][Full Text] [Related]
20. Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron.
Amano M; Otsu S; Uemura Y; Ichikawa Y; Matsumoto S; Higashi-Kuwata N; Matsushita S; Shimada S; Mitsuya H
Sci Rep; 2023 Oct; 13(1):17404. PubMed ID: 37833390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
